July 26, 2017 / 11:11 AM / 4 months ago

BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA

July 26 (Reuters) - Oncolytics Biotech Inc

* Oncolytics biotech® to present reolysin® safety data in combination with chemotherapy at esmo 2017 congress

* Oncolytics biotech inc - has been granted an end-of-phase 2 meeting with united states food and drug administration (fda), taking place in august 2017.

* Oncolytics biotech inc - company expects to announce outcome of meeting with fda in q4 of 2017. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below